financetom
Business
financetom
/
Business
/
NetApp Q4 Non-GAAP EPS, Revenue Increase; Q1, Fiscal 2025 Outlook Issued
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
NetApp Q4 Non-GAAP EPS, Revenue Increase; Q1, Fiscal 2025 Outlook Issued
May 30, 2024 1:33 PM

04:20 PM EDT, 05/30/2024 (MT Newswires) -- NetApp ( NTAP ) reported Q4 non-GAAP earnings late Thursday of $1.80 per diluted share, up from $1.54 a year earlier.

Analysts polled by Capital IQ expected $1.79.

Net revenue for the quarter ended April 26 was $1.67 billion, up from $1.58 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.65 billion.

The company said it expects Q1 non-GAAP EPS between $1.40 and $1.50 and net revenue between $1.46 billion and $1.61 billion. Analysts polled by Capital IQ expect $1.44 and $1.53 billion.

The company expects fiscal 2025 non-GAAP EPS between $6.80 and $7.00 and net revenue between $6.45 billion and $6.65 billion. Analysts surveyed by Capital IQ expect $6.73 and $6.52 billion, respectively.

Price: 116.00, Change: -0.50, Percent Change: -0.43

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NRG Energy's Q2 Net Income, Revenue Rise
NRG Energy's Q2 Net Income, Revenue Rise
Aug 8, 2024
07:50 AM EDT, 08/08/2024 (MT Newswires) -- NRG Energy ( NRG ) reported Q2 net income Thursday of $3.37 per diluted share, up from $1.25 a year earlier. Two analysts polled by Capital IQ expected $1.55. Revenue for the quarter ended June 30 was $6.66 billion, compared with $6.35 billion a year earlier. One analyst surveyed by Capital IQ expected...
Merck stops testing combo drug for lung cancer
Merck stops testing combo drug for lung cancer
Aug 8, 2024
Aug 8 (Reuters) - Merck ( MRK ) said on Thursday it had discontinued a trial testing a combination immunotherapy treatment in patients with a type of lung cancer after an interim analysis showed the drug was unlikely to succeed. The patients tested with a combination of its experimental drug, vibostolimab, with Keytruda experienced a higher rate of immune-related side...
Datadog's Q2 Adjusted Earnings, Revenue Rise; Fiscal 2024 Outlook Lifted
Datadog's Q2 Adjusted Earnings, Revenue Rise; Fiscal 2024 Outlook Lifted
Aug 8, 2024
07:49 AM EDT, 08/08/2024 (MT Newswires) -- Datadog ( DDOG ) reported Q2 adjusted earnings Thursday of $0.43 per diluted share, up from $0.29 a year earlier. Analysts polled by Capital IQ expected $0.36. Revenue for the quarter ended June 30 was $645.3 million, compared with $509.5 million a year earlier. Analysts surveyed by Capital IQ expected $625.1 million. The...
Robinhood's push into futures may not be easy if not free, J.P. Morgan says
Robinhood's push into futures may not be easy if not free, J.P. Morgan says
Aug 8, 2024
(Reuters) - Robinhood's entry into futures trading this year could be met with some caution by retail traders using its commission-free platform if it charges a fee, J.P. Morgan analysts said on Thursday. The company has not yet disclosed its plans, but orders for futures and options are often costlier to execute than stocks, which could result in it charging...
Copyright 2023-2026 - www.financetom.com All Rights Reserved